Nasdaq
$1.14▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.9MShares out 4.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 10.16After-hours26.10.17 05:308-KKey event#●●●
Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals announced the results of its Annual Meeting of Stockholders held on October 16, 2026. Shareholders approved the election of Class II directors and the ratification of CohnReznick LLP as the independent registered public accounting firm for the fiscal year 2026.…more
$1.14+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.18Pre-market26.09.18 13:15filedEFFECTOther
Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc. received notice of effectiveness from the SEC for its registration statement on September 17, 2026. This approval officially authorizes the company to proceed with its public offering to raise capital.…more
$1.14+0.00%vs prev closeView filingShare - 9.17After-hours26.09.18 05:52424B3Offering
Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is registering up to 1,500,000 shares of common stock for resale by Lincoln Park Capital Fund under an existing purchase agreement. The company may raise up to $2.8 million in additional gross proceeds through sales to Lincoln Park, which will be used for working capital and general corporate purposes.…more
$1.14+0.00%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.29Pre-market26.09.29 21:07#●●●#●●●#●●●
Acurx Enrolls First Patient in PATHFINDER Phase 2 Trial for Recurrent C. Difficile Infection…more
Acurx Pharmaceuticals has enrolled the first patient in its PATHFINDER Phase 2 clinical trial for patients with multiply recurrent C. difficile infection. The study results will support the company's planned FDA new drug application for the treatment.…more
$1.14+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.8After-hours26.09.09 05:39
●●●●●●●● ●●●●● ●●●●●●
Acurx Pharmaceuticals has filed a prospectus for an offering of 1.5 million shares. This move may negatively impact the stock price due to potential shareholder dilution.…more
$1.14+0.00%vs prev closeShareBenzinga
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report